AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
AI can make mistakes. Verify answers against the original sources before relying on them.
bitolterol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| bronchodilators, phenethylamine derivatives | 384 | 30392-40-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
a short-acting beta2 adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and COPD
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 3.606 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 2.360 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 5.546 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 51.286 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 0.720 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 2.260 | % | High | 1 |
| herg | hERG pIC50 | 5.647 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 299.226 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 189.234 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 0.920 | % | High | 1 |
| kinase-safety-class | ACVR2B,AKT1,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK1,JAK2,JAK3,KIT,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MARK4,MET,MTOR,NTRK2,PAK4,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK | 53 | |||
| kinase-selectivity-class | ACVR2B,AXL,EIF2AK3,GRK2,PDK4 | 5 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 7.295 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 368.978 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 2.700 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 17.783 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 6.810 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 283.139 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 11.180 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 1.250 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 22.751 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 28, 1984 | FDA | SANOFI AVENTIS US |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | R03AC17 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Selective beta-2-adrenoreceptor agonists |
| CHEBI has role | CHEBI:35522 | β-adrenergic agonist |
| CHEBI has role | CHEBI:35523 | bronchodilator agent |
| CHEBI has role | CHEBI:49167 | anti-asthmatic drug |
| CHEBI has role | CHEBI:50266 | prodrug |
| MeSH PA | D000318 | Adrenergic beta-Agonists |
| MeSH PA | D000322 | Adrenergic Agonists |
| MeSH PA | D001993 | Bronchodilator Agents |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018663 | Adrenergic Agents |
| MeSH PA | D018927 | Anti-Asthmatic Agents |
| MeSH PA | D019141 | Respiratory System Agents |
| MeSH PA | D058666 | Adrenergic beta-2 Receptor Agonists |
Related Drugs by ATC class:
R03AC Selective beta-2-adrenoreceptor agonists 17 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Bronchiectasis | indication | 12295008 | DOID:9563 |
| Bronchitis | indication | 32398004 | DOID:6132 |
| Pulmonary emphysema | indication | 87433001 | |
| Asthma | indication | 195967001 | DOID:2841 |
| Asthma management | indication | 406162001 | |
| Acute exacerbation of asthma | indication | 708038006 | |
| Bronchospasm Prevention | indication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 14.0 | acidic |
| pKa2 | 9.19 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Beta-2 adrenergic receptor | GPCR | AGONIST | CHEMBL | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019101 | VUID |
| N0000147359 | NUI |
| D00684 | KEGG_DRUG |
| 30392-41-7 | SECONDARY_CAS_RN |
| 19499 | RXNORM |
| C0053817 | UMLSCUI |
| CHEBI:3133 | CHEBI |
| CHEMBL1201295 | ChEMBL_ID |
| CHEMBL1200405 | ChEMBL_ID |
| DB00901 | DRUGBANK_ID |
| C011685 | MESH_SUPPLEMENTAL_RECORD_UI |
| 3855 | INN_ID |
| 9KY0QXD6LI | UNII |
| 35330 | PUBCHEM_CID |
| 1209 | MMSL |
| 4292 | MMSL |
| d00754 | MMSL |
| 387233000 | SNOMEDCT_US |
| 412217002 | SNOMEDCT_US |
| 41985001 | SNOMEDCT_US |
| 4019101 | VANDF |
| 4019636 | VANDF |
| 001816 | NDDF |
| 004733 | NDDF |
| 9KY0QXD6LI | INXIGHT DRUGS |
Pharmaceutical products:
None